Briakinumab (Synonyms: ABT-874) |
| Catalog No.GC68807 |
Briakinumab (ABT-874) is a fully human monoclonal antibody that targets and neutralizes IL-12/23p40. Briakinumab specifically targets and neutralizes both IL-12 and IL-23. It is being studied for its potential use in rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 339308-60-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Review for Briakinumab
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
Review for Briakinumab
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *